Drug Master File (DMF) system in the US MCQs With Answer

Introduction: Drug Master Files (DMFs) are central to regulatory submissions in the US when manufacturers need to protect confidential chemistry, manufacturing and controls (CMC) information while allowing drug applicants to reference that information in their applications. This quiz-focused blog presents targeted multiple-choice questions designed for M.Pharm students studying Regulatory Aspects of Drugs & Cosmetics. The questions cover DMF types, submission and maintenance practices, Letters of Authorization, confidentiality, FDA review expectations, and practical DMF management. Use these MCQs to deepen your understanding of how DMFs facilitate regulatory review, protect proprietary data, and interact with NDAs, ANDAs and other regulatory submissions in the US system.

Q1. What is the primary purpose of a Drug Master File (DMF) in the US regulatory system?

• To obtain FDA approval for a drug product directly
• To provide proprietary CMC information to FDA that can be referenced by multiple applicants without disclosing to them
• To replace the need for an applicant to submit an NDA or ANDA
• To serve as a public registry of all manufacturing sites

Correct Answer: To provide proprietary CMC information to FDA that can be referenced by multiple applicants without disclosing to them

Q2. Which DMF type is most commonly used for active pharmaceutical ingredients (APIs) and related intermediates?

• Type I
• Type II
• Type III
• Type IV

Correct Answer: Type II

Q3. Which DMF type is specifically intended for packaging materials that may come into contact with a drug product?

• Type II
• Type III
• Type IV
• Type V

Correct Answer: Type III

Q4. Which statement correctly describes a Letter of Authorization (LOA) in the DMF process?

• An LOA is issued by FDA to authorize a DMF holder to supply the API
• An LOA is issued by the DMF holder to allow an applicant to reference the DMF in its regulatory submission
• An LOA is a public document summarizing a DMF
• An LOA is a fee payment acknowledgement for DMF submission

Correct Answer: An LOA is issued by the DMF holder to allow an applicant to reference the DMF in its regulatory submission

Q5. Which of the following is true about FDA approval of a DMF?

• FDA issues an approval letter when a DMF is acceptable
• DMFs are approved like NDAs and receive formal approval
• FDA neither approves nor disapproves DMFs; the DMF is a reference that may be reviewed during application assessment
• DMFs are automatically accepted without any FDA review

Correct Answer: FDA neither approves nor disapproves DMFs; the DMF is a reference that may be reviewed during application assessment

Q6. Which DMF type is typically used for excipients, colorants, and flavoring agents?

• Type II
• Type III
• Type IV
• Type V

Correct Answer: Type IV

Q7. What action should a DMF holder take when there is a significant change to the manufacturing process described in the DMF?

• Do nothing until FDA requests information
• Notify all applicants who have referenced the DMF and submit an amendment to the DMF describing the change
• Withdraw the DMF and create a new one
• Only update the next Letter of Authorization

Correct Answer: Notify all applicants who have referenced the DMF and submit an amendment to the DMF describing the change

Q8. Which of the following best describes Type V DMFs?

• Type V is for APIs and is the most common DMF type
• Type V is for packaging components exclusively
• Type V is a miscellaneous category for other types of confidential information and generally requires FDA acceptance before use
• Type V is obsolete and no longer used

Correct Answer: Type V is a miscellaneous category for other types of confidential information and generally requires FDA acceptance before use

Q9. Which format does FDA strongly encourage for DMF submissions to improve review efficiency?

• Paper paper-based binder only
• eCTD (electronic Common Technical Document) format
• Handwritten dossiers
• Audio recordings of manufacturing processes

Correct Answer: eCTD (electronic Common Technical Document) format

Q10. Who is responsible for maintaining the accuracy and currency of the information within a DMF?

• The FDA review division
• The applicant who references the DMF
• The DMF holder (owner)
• The contract manufacturing organization only

Correct Answer: The DMF holder (owner)

Q11. If an ANDA applicant wants to reference a DMF, what must the applicant submit to FDA with the ANDA?

• The entire DMF document in duplicate
• A Letter of Authorization (LOA) or equivalent information indicating authorization to reference specified DMF sections
• A signed contract between the applicant and the DMF holder
• A copy of the DMF holder’s manufacturing license

Correct Answer: A Letter of Authorization (LOA) or equivalent information indicating authorization to reference specified DMF sections

Q12. What can happen to a DMF that is not updated or referenced for a long period?

• It is automatically converted into a public master file
• FDA may place it on inactive/closed status and it may no longer be accepted for referencing
• It becomes valid for indefinite automatic use by any applicant
• The DMF number is transferred to the applicant who last referenced it

Correct Answer: FDA may place it on inactive/closed status and it may no longer be accepted for referencing

Q13. Which of these is NOT an expected element in a complete DMF for an API?

• Detailed description of manufacturing process and controls
• Specifications and analytical methods for the API
• Clinical efficacy trial results for the API in humans
• Stability data and container-closure information

Correct Answer: Clinical efficacy trial results for the API in humans

Q14. True or False: A DMF holder must pay a submission fee to FDA when submitting a DMF.

• True — a fee is required for each DMF submitted
• False — FDA does not charge a fee specifically for submitting a DMF
• True — but only for Type II DMFs
• False — fees are charged only when the DMF is referenced

Correct Answer: False — FDA does not charge a fee specifically for submitting a DMF

Q15. Which of the following best explains why an applicant might prefer to reference a DMF rather than include proprietary CMC in its own submission?

• Referencing a DMF eliminates the need for quality data in the application
• Referencing a DMF protects proprietary manufacturing details while allowing FDA access during review
• Referencing a DMF automatically shortens review timelines
• Referencing a DMF transfers regulatory responsibility from the applicant to the DMF holder

Correct Answer: Referencing a DMF protects proprietary manufacturing details while allowing FDA access during review

Q16. Which regulatory action may FDA take if critical deficiencies are found in the DMF material during review of a referencing application?

• Automatically approve the application and send information requests to the DMF holder later
• Issue information requests to the applicant and DMF holder; approval of the referencing application may be delayed until issues are resolved
• Immediately invalidate the DMF number
• Transfer the DMF ownership to FDA

Correct Answer: Issue information requests to the applicant and DMF holder; approval of the referencing application may be delayed until issues are resolved

Q17. Historically, which DMF type was used for manufacturing sites but is no longer commonly used by FDA?

• Type I
• Type II
• Type III
• Type IV

Correct Answer: Type I

Q18. When a DMF holder provides an LOA, what key information should the LOA usually contain?

• Only the DMF holder’s tax ID number
• Identification of the DMF number, the authorized applicant, specific sections authorized, and effective date/signature
• Sales and distribution forecasts for the API
• The pricing terms for supplying the API to the applicant

Correct Answer: Identification of the DMF number, the authorized applicant, specific sections authorized, and effective date/signature

Q19. Which statement about public access to DMF contents is correct?

• All DMF contents are publicly posted on the FDA website
• Applicants can view full DMF contents after paying a fee to FDA
• DMF contents are confidential and not publicly disclosed; access is limited to FDA and authorized applicants
• DMF contents become public once referenced in an NDA

Correct Answer: DMF contents are confidential and not publicly disclosed; access is limited to FDA and authorized applicants

Q20. Which practice helps ensure a DMF remains acceptable for referencing by applicants?

• Never responding to FDA inquiries about the DMF
• Maintaining timely amendments, submitting annual status updates as appropriate, and promptly issuing LOAs to applicants
• Changing the DMF holder’s name without notifying FDA
• Only updating the DMF once every ten years

Correct Answer: Maintaining timely amendments, submitting annual status updates as appropriate, and promptly issuing LOAs to applicants

Download